RE:AstraZeneca's ADC disappoints - on severe adverse eventsJuly 08, 2024 - Companies like Pfizer is in early clinical trials with its auristatin-based (ex. chemotherapy) ADC with a checkpoint inhibitor for a synergistic effect - providing further insight that ONCY's pelareorep is prepared to facilitate the effectiveness of the ADC - anti-PD-(L)1 CPI doublet by remodeling the TME thus preparing the extracellular envionment for the addition of the CPI and overcoming T-cell exhaustion.
https://jitc.bmj.com/content/11/10/e007572
https://pubmed.ncbi.nlm.nih.gov/32115527/